Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy
Aim: to evaluate the pharmacoeconomic efficacy of the application of the atesolizumab (PD-L1 inhibitor) preparation compared with other control point inhibitors (PD-1 inhibitors) in patients with advanced non-small cell lung cancer (NSCLC) after chemothe rapy.Materials and methods. Study design incl...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2020-04-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/338 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394501290819584 |
|---|---|
| author | S. K. Zyryanov I. N. Diyakov |
| author_facet | S. K. Zyryanov I. N. Diyakov |
| author_sort | S. K. Zyryanov |
| collection | DOAJ |
| description | Aim: to evaluate the pharmacoeconomic efficacy of the application of the atesolizumab (PD-L1 inhibitor) preparation compared with other control point inhibitors (PD-1 inhibitors) in patients with advanced non-small cell lung cancer (NSCLC) after chemothe rapy.Materials and methods. Study design included a retrospective analysis of literature data and modeling. Based on the calculations conducted in a Microsoft Excel model, we analyzed the effect of minimizing costs on using comparable drugs with comparable efficacy; we evaluated how the provision of all patients with NSCLC will impact the health system budget taking into consideration the fact that all these patients are currently provided with PD-1 inhibitors in the second and third lines and with the atezolizumab preparation. For calculations, we used the prices stated in the state register of maximum selling prices; the weighted average maximum wholesale premium was calculated according to the Federal Antimonopoly Service (FAS). Results. In the analysis of cost minimization, atesolizumab proved itself to be highly clinically and economically effective. It allowed reducing the costs by 28.6% over 3 years compared with the use of nivolumab, and by 31.3% compared with the use of pembrolizumab in the second- and third-line NSCLC treatment regimen. Analysis of the impact on the budget showed that if all 848 patients currently receiving PD-1/PD-L1 inhibitors in the second- and third-line NSCLC treatment regimens had been initially provided with atesolizumab, this would have reduced the pressure on budget by 21.90% or 664.25 million rubles for 3 years.Conclusion. The use of the atesolizumab preparation is pharmacoeconomically reasonable and appropriate in comparison with the use of nivolumab and pembrolizumab. It will allow reducing the cost of PD-1/PD-L1 inhibitors in the second- and third-line NSCLC treatment regimens. |
| format | Article |
| id | doaj-art-edc08d25fb9e433daaa0898dd130a8aa |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2020-04-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-edc08d25fb9e433daaa0898dd130a8aa2025-08-20T03:39:57ZrusIRBIS LLCФармакоэкономика2070-49092070-49332020-04-0113151210.17749/2070-4909.2020.13.1.5-12285Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapyS. K. Zyryanov0I. N. Diyakov1Peoples’ Friendship University Of RussiaResearch Institute of Vaccines and Serums named after I.I. Mechnikov ; Scientific and Practical Center for the Study of the Problems of Rational Pharmacotherapy and PharmacoeconomicsAim: to evaluate the pharmacoeconomic efficacy of the application of the atesolizumab (PD-L1 inhibitor) preparation compared with other control point inhibitors (PD-1 inhibitors) in patients with advanced non-small cell lung cancer (NSCLC) after chemothe rapy.Materials and methods. Study design included a retrospective analysis of literature data and modeling. Based on the calculations conducted in a Microsoft Excel model, we analyzed the effect of minimizing costs on using comparable drugs with comparable efficacy; we evaluated how the provision of all patients with NSCLC will impact the health system budget taking into consideration the fact that all these patients are currently provided with PD-1 inhibitors in the second and third lines and with the atezolizumab preparation. For calculations, we used the prices stated in the state register of maximum selling prices; the weighted average maximum wholesale premium was calculated according to the Federal Antimonopoly Service (FAS). Results. In the analysis of cost minimization, atesolizumab proved itself to be highly clinically and economically effective. It allowed reducing the costs by 28.6% over 3 years compared with the use of nivolumab, and by 31.3% compared with the use of pembrolizumab in the second- and third-line NSCLC treatment regimen. Analysis of the impact on the budget showed that if all 848 patients currently receiving PD-1/PD-L1 inhibitors in the second- and third-line NSCLC treatment regimens had been initially provided with atesolizumab, this would have reduced the pressure on budget by 21.90% or 664.25 million rubles for 3 years.Conclusion. The use of the atesolizumab preparation is pharmacoeconomically reasonable and appropriate in comparison with the use of nivolumab and pembrolizumab. It will allow reducing the cost of PD-1/PD-L1 inhibitors in the second- and third-line NSCLC treatment regimens.https://www.pharmacoeconomics.ru/jour/article/view/338common non-small cell lung cancersecond line of therapythird line of therapycontrol point inhibitorspd-1/pd-l1 inhibitorsatesolizumabpembrolizumabnivolumabcost minimizationbudget impact |
| spellingShingle | S. K. Zyryanov I. N. Diyakov Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy Фармакоэкономика common non-small cell lung cancer second line of therapy third line of therapy control point inhibitors pd-1/pd-l1 inhibitors atesolizumab pembrolizumab nivolumab cost minimization budget impact |
| title | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy |
| title_full | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy |
| title_fullStr | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy |
| title_full_unstemmed | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy |
| title_short | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy |
| title_sort | pharmacoeconomic efficacy of atesolizumab compared with other pd 1 inhibitors in patients with advanced non small cell lung cancer after chemotherapy |
| topic | common non-small cell lung cancer second line of therapy third line of therapy control point inhibitors pd-1/pd-l1 inhibitors atesolizumab pembrolizumab nivolumab cost minimization budget impact |
| url | https://www.pharmacoeconomics.ru/jour/article/view/338 |
| work_keys_str_mv | AT skzyryanov pharmacoeconomicefficacyofatesolizumabcomparedwithotherpd1inhibitorsinpatientswithadvancednonsmallcelllungcancerafterchemotherapy AT indiyakov pharmacoeconomicefficacyofatesolizumabcomparedwithotherpd1inhibitorsinpatientswithadvancednonsmallcelllungcancerafterchemotherapy |